New IL-2 drug aims to supercharge immune attack on Hard-to-Treat cancers
Disease control
Ongoing
This study tests an experimental drug called TransCon IL-2 β/γ, which is designed to boost the immune system's ability to fight advanced solid tumors. About 320 adults with cancers like ovarian, melanoma, lung, or cervical cancer will receive the drug alone or combined with other…
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated May 17, 2026 03:58 UTC